Literature summary for 2.5.1.10 extracted from

Liu, Q.; Miao, Y.; Wang, X.; Lv, G.; Peng, Y.; Li, K.; Li, M.; Qiu, L.; Lin, J.
Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors (2020), Eur. J. Med. Chem., 186, 111905 .

Search for more literature for 2.5.1.10

Inhibitors

Inhibitors	Comment	Organism	Structure
ZINC04011866	0.01 mM, 29.9% inhibition	Homo sapiens
ZINC04043066	0.01 mM, 25.3% inhibition	Homo sapiens
ZINC04064228	0.01 mM, 11.5% inhibition	Homo sapiens
ZINC04082083	0.01 mM, 17.3% inhibition	Homo sapiens
ZINC04763743	0.01 mM, 29.4% inhibition	Homo sapiens
ZINC05037497	0.01 mM, 29.3% inhibition	Homo sapiens
ZINC06894343	0.01 mM, 28.9% inhibition	Homo sapiens
ZINC09224949	0.01 mM, 23.5% inhibition	Homo sapiens
ZINC12377242	0.01 mM, 13% inhibition	Homo sapiens
ZINC15868804	0.01 mM, 24% inhibition	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	P14324	-	-

Purification (Commentary)

Purification (Comment)	Organism
-	Homo sapiens

Synonyms

Synonyms	Comment	Organism
farnesyl pyrophosphate synthase	-	Homo sapiens
FPPS	-	Homo sapiens

General Information

General Information	Comment	Organism
drug target	the enzyme plays a significant role in the disease-related cell signaling pathway, and the inhibition of the enzyme is a potential approach for treating FPPS-regulated diseases	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)